SEARCH

SEARCH BY CITATION

References

  • 1
    The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, an Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 2
    European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10111053.
  • 3
    MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765774.
  • 4
    Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:24862497.
  • 5
    Barrios V, Campuzano R, Peña G, et al. Cardiovascular risk stratification in hypertensive patients attended in primary care setting and its impact on the antihypertensive treatment. The DIORISC study. Hipertensión. 2002;19:114120.
  • 6
    Barrios V, Martinez M, Tomas JP, et al. Clinical profile of a hypercholesterolemic Spanish population and differences between genders. LIPYCARE study. Hipertensión. 2004;21:395402.
  • 7
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:14231427.
  • 8
    Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:13051315.
  • 9
    Sever P, Dahlö B, Poulter N, et al, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:11491158.
  • 10
    Llisterri JL, Rodríguez G, Alonso FJ, et al. Blood pressure control in Spanish hypertensive patients in Primary Health Care Centres. PRESCAP 2002 Study. Med Clin (Barc). 2004;122:165171.
  • 11
    Coca Payeras A. Blood pressure control among treated hypertensive patients by Primary Care in Spain. The 2003 Controlpres study. Hipertensión. 2005;22:514.
  • 12
    Alvarez-Sala LA, Suarez C, Mantilla T, et al. The PREVENCAT study: control of cardiovascular risk in primary care. Med Clin (Barc). 2005;124:406410.
  • 13
    Fagard RH, Van Den Enden M, Leeman M, et al. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens. 2002;20:12971302.
  • 14
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • 15
    Thomas F, Rudnichi A, Bacri AM, et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension. 2001;37:12561261.
  • 16
    Johnson ML, Pietz K, Battleman DS, et al. Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care. 2006;44:3946.
  • 17
    Ferdinand KC, Kleinpeter MA. Management of hypertension and dyslipidemia. Curr Hypertens Rep. 2006;8:489496.
  • 18
    de la Sierra A, Romero R, Bonet J, et al. Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population. Med Clin (Barc). 2006;126:406409.
  • 19
    Garcia O, Lozano JV, Vegazo O, et al. Control of blood pressure in diabetic patients in primary care setting. DIAPA study. Med Clin (Barc). 2003;120:529534.
  • 20
    de la Sierra A, Ruilope LM, Coca A, et al. Relationship between cardiovascular risk profile and antihypertensive drug use. Med Clin (Barc). 2000;115:4145.
  • 21
    Conroy RM, Pyorala K, Fitzgerald AP, et al, for the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:9871003.
  • 22
    Juanatey JR, Ezquerra EA, Vidal JV, et al. Impact of hypertension in cardiac diseases in Spain. The CARDIOTENS Study 1999. Rev Esp Cardiol. 2001;54:139149.
  • 23
    Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension. 2004;43:13381344.
  • 24
    Banegas JR. Epidemiology of arterial hypertension in Spain. Present situation and perspectivas. Hipertensión. 2005;22:353362.
  • 25
    Backlund L, Bring J, Strender LE. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Prim Health Care Res Dev. 2004;5:145152.
  • 26
    Salisbury C, Fahey T. Overcoming clinical inertia in the management of hypertension. CMAJ. 2006;174:12851286.
  • 27
    Garcia Ruiz FJ, Marin Ibanez A, Perez-Jimenez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics. 2004;22(suppl 3):112.
  • 28
    ELIPSE study investigators. Secondary prevention of ischemic heart disease in the Cuidad Real Province, Spain. Effectiveness of lipid-lowering therapy in primary health care. Med Clin (Barc). 2000;115:321325.
  • 29
    Barbanza study investigators. Characteristics of the patients with heart disease in a health area of A Coruna province. Barbanza 2000 study. Estudio Barbanza 2000. Rev Clin Esp. 2003;203:570576.
  • 30
    Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459467.
  • 31
    de Velasco JA, Llargues E, Fito R, et al. Risk factor prevalence and drug treatment in coronary patients at hospital discharge. Results of a national multicenter registry (3C Program). Rev Esp Cardiol. 2001;54:159168.
  • 32
    De Velasco JA, Cosin J, Lopez-Sendon JL, et al. New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study. Rev Esp Cardiol. 2002;55:801809.